Benzinga
02 Sept 2026, 15:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
TScan Therapeutics is implementing a workforce reduction of approximately 75% as part of a major corporate reorganization. — A massive staff cut of 75% indicates severe distress and a drastic reduction in operational capacity.
-0.80TScan has paused new enrollment in its Phase 3 ALLOHA-2 study for hematologic malignancies due to funding constraints. — Halting a late-stage Phase 3 trial due to lack of cash is a critical red flag for a clinical-stage biotech company.
-0.70The company is pivoting its strategy to prioritize its in vivo solid tumor pipeline over its existing programs. — While a strategic pivot can be positive long-term, in this context it appears to be a forced move driven by capital constraints.
-0.30Continue reading
6 related stories
Search tags
TScan has advanced two product candidates targeting PRAME and MAGE-A4 into IND-enabling studies. — Progressing new candidates toward clinical trials provides a potential future catalyst for recovery.
+0.20Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
5h ago
